指南与共识消化、代谢与肾脏急症儿科与产科急症

戊二酸尿症1型的诊断与管理建议:第三版修订

Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision.
指南 / 共识 · J Inherit Metab Dis · 2022-11-17
一句话结论戊二酸尿症1型第三版循证建议:新生儿筛查是症状前启动低赖氨酸饮食、肉碱补充及应急治疗的前提,可显著改善神经结局。

戊二酸尿症1型是赖氨酸代谢的罕见遗传性神经代谢病,由GCDH基因变异导致线粒体戊二酰辅酶A脱氢酶缺乏,使戊二酸、3-羟基戊二酸、戊烯二酸和戊二酰肉碱蓄积,可通过气相色谱/质谱(有机酸)和串联质谱(酰基肉碱)检出。多数未治疗个体在3岁(至6岁)前因感染、发热或手术诱发急性纹状体损伤,导致不可逆的运动障碍;部分患者隐匿起病。新生儿筛查是症状前启动低赖氨酸饮食、肉碱补充及分解代谢期强化应急治疗的前提,联合治疗显著改善神经结局;症状出现后开始治疗不能逆转已存在的运动障碍。本第三版循证建议旨在重新评估既往建议并纳入新研究证据。

要点

  • 新生儿筛查是症状前启动代谢治疗(低赖氨酸饮食、肉碱补充、应急治疗)的前提,联合治疗显著改善神经结局。
  • 症状出现后开始治疗不能逆转纹状体损伤所致的运动障碍。
  • 多数未治疗个体在3岁(至6岁)前因感染、发热或手术诱发急性纹状体损伤,导致不可逆的运动障碍。
  • 饮食治疗在纹状体损伤易感期后(即6岁后)可放松,但其对长期结局的影响仍不清楚。
  • 根据残余GCDH活性定义了生化高排泄和低排泄表型;高排泄组更易出现纹状体外异常和认知功能障碍,以及慢性肾衰竭。

适用人群与场景

  • 戊二酸尿症1型个体,包括经新生儿筛查发现的无症状者及已出现症状的患者。
  • 根据残余GCDH活性分为生化高排泄和低排泄表型;高排泄组更易出现纹状体外异常、认知功能障碍和慢性肾衰竭。

诊断标准与关键阈值

  • GCDH基因致病性变异(细胞遗传学位置:19p13.13)导致线粒体戊二酰辅酶A脱氢酶(GCDH)缺乏。
  • 代谢物蓄积:戊二酸、3-羟基戊二酸、戊烯二酸和戊二酰肉碱,可通过气相色谱/质谱(有机酸)和串联质谱(酰基肉碱)检出。
  • 根据残余GCDH活性定义生化高排泄和低排泄表型。

处置流程与药物剂量

  • 新生儿筛查后症状前启动代谢治疗:低赖氨酸饮食、肉碱补充和分解代谢期强化应急治疗。
  • 饮食治疗在纹状体损伤易感期后(即6岁后)可放松,但其对长期结局的影响仍不清楚。
  • 症状出现后开始治疗不能逆转纹状体损伤所致的运动障碍。

红旗征与不能漏的情况

  • 感染性疾病、发热或手术可诱发急性纹状体损伤,导致不可逆的运动障碍。
  • 部分患者纹状体损伤可隐匿起病。
  • 高排泄组可出现纹状体外异常、认知功能障碍和慢性肾衰竭。

研究设计与关键结果

  • 本第三版循证建议重新评估既往建议(Boy等,J Inherit Metab Dis,2017;40(1):75-101;Kolker等,J Inherit Metab Dis 2011;34(3):677-694;Kolker等,J Inherit Metab Dis,2007;30(1):5-22),并纳入关于表型多样性演变以及非干预变量和治疗质量对临床结局影响的新研究证据。

证据类型、等级与局限

  • 证据类型:循证建议(第三版修订)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 新生儿筛查是症状前启动代谢治疗的前提,联合低赖氨酸饮食、肉碱补充和应急治疗可显著改善神经结局。
  • 症状出现后开始治疗不能逆转已存在的运动障碍,因此应尽早通过新生儿筛查启动治疗。
  • 饮食治疗在6岁后(纹状体损伤易感期后)可放松,但其对长期结局的影响仍不清楚。

指南或共识出处

  • Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision(J Inherit Metab Dis)。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Glutaric aciduria type 1 is a rare inherited neurometabolic disorder of lysine metabolism caused by pathogenic gene variations in GCDH (cytogenic location: 19p13.13), resulting in deficiency of mitochondrial glutaryl-CoA dehydrogenase (GCDH) and, consequently, accumulation of glutaric acid, 3-hydroxyglutaric acid, glutaconic acid and glutarylcarnitine detectable by gas chromatography/mass spectrometry (organic acids) and tandem mass spectrometry (acylcarnitines). Depending on residual GCDH activity, biochemical high and low excreting phenotypes have been defined. Most untreated individuals present with acute onset of striatal damage before age 3 (to 6) years, precipitated by infectious diseases, fever or surgery, resulting in irreversible, mostly dystonic movement disorder with limited life expectancy. In some patients, striatal damage develops insidiously. In recent years, the clinical phenotype has been extended by the finding of extrastriatal abnormalities and cognitive dysfunction, preferably in the high excreter group, as well as chronic kidney failure. Newborn screening is the prerequisite for pre-symptomatic start of metabolic treatment with low lysine diet, carnitine supplementation and intensified emergency treatment during catabolic episodes, which, in combination, have substantially improved neurologic outcome. In contrast, start of treatment after onset of symptoms cannot reverse existing motor dysfunction caused by striatal damage. Dietary treatment can be relaxed after the vulnerable period for striatal damage, that is, age 6 years. However, impact of dietary relaxation on long-term outcomes is still unclear. This third revision of evidence-based recommendations aims to re-evaluate previous recommendations (Boy et al., J Inherit Metab Dis, 2017;40(1):75-101; Kolker et al., J Inherit Metab Dis 2011;34(3):677-694; Kolker et al., J Inherit Metab Dis, 2007;30(1):5-22) and to implement new research findings on the evolving phenotypic diversity as well as the impact of non-interventional variables and treatment quality on clinical outcomes.

来源:J Inherit Metab Dis,查看原文。版权归原作者所有。

参考来源

  1. Boy N, Mühlhausen C, Maier EM, et al. Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision. J Inherit Metab Dis. 2022. PMID: 36221165. doi:10.1002/jimd.12566

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。